

Date: 10 November 2023

To
Corporate Relationship Department
BSE Limited,
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

To
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051.

Dear Sir/Ma’am,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

.....

USFDA Inspection of Shilpa Medicare Ltd. Unit 4, Jadcherla, Telangana.

This is to inform you that Shilpa Medicare Limited, Unit 4, Jadcherla; Telangana, India had an un-announced USFDA inspection from 30th October 2023 until 9th November 2023.

The previous USFDA inspection for this facility was in February 2020. This was a “for cause” inspection. The inspection ended with ten observations in Form 483; none of the observations has been listed as repeat observation. None of the observations relate to data integrity.

This Unit of Shilpa Medicare is engaged in the manufacture, testing and distribution of sterile Injections and non-sterile tablets and Capsule finished dosage forms in the US, Europe and rest of the world markets.

The Company intends to respond to the observations within the stipulated time and is committed for the satisfactory resolution of the USFDA observations.

This is for your information and necessary records.
For Shilpa Medicare Limited,

Ritu Tiwary
Company Secretary & Compliance Officer